RDY Dr. Reddy's Laboratories Limited: תחזית צמיחת רווח נקי למניה לשנה הבאה

סמל ולוגו של המותג drreddys.com (RDY)

The dynamics of consensus EPS forecasts for the coming year show that Dr. Reddy's Laboratories (RDY) has reached the level of 34.30. Growth is supported by low costs and the development of complex injectable products. This positive trajectory is driven by the launch of biosimilars into the US market and oncology partnerships. Stable potential is ensured by attracting leading chemists through large-scale investments in modern research centers.

RDY: תחזית צמיחת רווח נקי למניה אחת לשנה הבאה Dr. Reddy's Laboratories Limited 04.07.2022 - 17.11.2026

Dr. Reddy's Lab - פילוחים אנליטיים ומדדי מפתח (RDY)

- מחיר מניה וקונצנזוס הערכת שווי:
ניתוח ראשוני של החברה:Dr. Reddy's Laboratories
מוצר עיקרי של Dr. Reddy's Laboratories Limited

For Dr. Reddy's Laboratories (RDY), this indicator serves as a tool for assessing future profitability amid a high dependence on external contractors. The forward earnings per share trend is based on the analyst consensus for annual EPS changes, reflecting the expected percentage growth in net income. The increase in this metric confirms the efficiency of generic drug development outsourcing and logistics optimization. The stability of this line testifies to the fundamental resilience of the company's business model.